Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study
Identificadores
Identificadores
Data de publicación
2011Título da revista
BMC MUSCULOSKELETAL DISORDERS
Tipo de contido
Artigo